FY2025 EPS Forecast for Vera Therapeutics Reduced by Analyst

Vera Therapeutics, Inc. (NASDAQ:VERA) – Equities researchers at HC Wainwright lowered their FY2025 earnings estimates for Vera Therapeutics in a report issued on Monday, June 2nd. HC Wainwright analyst A. He now forecasts that the company will post earnings per share of ($3.44) for the year, down from their prior forecast of ($3.42). HC Wainwright currently has a “Buy” rating and a $85.00 price target on the stock. The consensus estimate for Vera Therapeutics’ current full-year earnings is ($2.89) per share. HC Wainwright also issued estimates for Vera Therapeutics’ Q4 2025 earnings at ($0.86) EPS, Q1 2026 earnings at ($0.81) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.84) EPS, Q4 2026 earnings at ($0.20) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at $1.03 EPS, FY2028 earnings at $3.86 EPS and FY2029 earnings at $6.06 EPS.

A number of other research firms have also commented on VERA. Wedbush reduced their price objective on shares of Vera Therapeutics from $34.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Cantor Fitzgerald cut their price target on shares of Vera Therapeutics from $107.00 to $100.00 and set an “overweight” rating on the stock in a report on Wednesday, May 7th. Scotiabank raised their price objective on shares of Vera Therapeutics from $55.00 to $65.00 and gave the stock a “sector outperform” rating in a research note on Monday. JPMorgan Chase & Co. lowered their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 4th. Finally, Guggenheim increased their target price on Vera Therapeutics from $59.00 to $61.00 and gave the company a “buy” rating in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $65.00.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA opened at $32.00 on Wednesday. The stock’s fifty day simple moving average is $22.26 and its 200 day simple moving average is $31.86. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of -12.26 and a beta of 1.13. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.61. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). During the same period in the previous year, the business earned ($0.56) earnings per share.

Institutional Trading of Vera Therapeutics

Institutional investors have recently bought and sold shares of the company. Barclays PLC raised its stake in shares of Vera Therapeutics by 94.1% during the 3rd quarter. Barclays PLC now owns 85,395 shares of the company’s stock worth $3,774,000 after purchasing an additional 41,394 shares in the last quarter. KBC Group NV increased its holdings in Vera Therapeutics by 127.2% in the fourth quarter. KBC Group NV now owns 2,477 shares of the company’s stock worth $105,000 after buying an additional 1,387 shares during the last quarter. Jennison Associates LLC increased its holdings in Vera Therapeutics by 82.0% in the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company’s stock worth $34,418,000 after buying an additional 366,763 shares during the last quarter. Legato Capital Management LLC raised its position in Vera Therapeutics by 56.0% during the fourth quarter. Legato Capital Management LLC now owns 13,454 shares of the company’s stock valued at $569,000 after acquiring an additional 4,831 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Vera Therapeutics by 12.5% in the fourth quarter. Rhumbline Advisers now owns 58,589 shares of the company’s stock valued at $2,478,000 after acquiring an additional 6,515 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.